Table 1.
Participant demographics, disease history and sample pathology.
| Sensitivity and specificity analysis population [N = 355] | |||
|---|---|---|---|
| Total cohort | Cases [N = 63] | Controls [N = 292] | |
| Age [years], n [IQR] | |||
| Median | 52 [39–62] | 55 [47–67] | 51 [38–62] |
| Sex, n [%] | |||
| Female | 162 [45.6] | 19 [30.2] | 143 [49.0] |
| Male | 193 [54.4] | 44 [69.8] | 149 [51.0] |
| Race, n [%] | |||
| White | 330 [93] | 58 [92.1] | 272 [93.2] |
| Black or African American | 14 [3.9] | 1 [1.6] | 13 [4.5] |
| Asian | 5 [1.4] | 2 [3.2] | 3 [1.0] |
| Other | 6 [1.7] | 2 [3.2] | 4 [1.4] |
| Ethnicity, n [%] | |||
| Hispanic or Latino | 18 [5.1] | 4 [6.4] | 14 [4.8] |
| Not Hispanic or Latino | 337 [94.9] | 59 [93.7] | 278 [95.2] |
| Disease status, n [%] | |||
| Crohn’s | 128 [36.1] | 21 [33.3] | 107 [36.6] |
| Ulcerative colitis | 222 [62.5] | 40 [63.5] | 182 [62.3] |
| Indeterminate colitis | 5 [1.4] | 2 [3.2] | 3 [1.0] |
| Primary sclerosing cholangitis [PSC], n [%] | |||
| Yes | 36 [10.1] | 50 [79.4] | 269 [92.1] |
| No | 319 [89.9] | 13 [20.6] | 23 [7.9] |
| IBD duration [years], n [IQR] | |||
| Median | 16 [11–25] | 18 [11–30] | 16 [11–24] |
| History of dysplasia [≥ 1 year prior to enrolment], n [%] | |||
| Yes | 11 [3.1] | 9 [14.3] | 2 [0.7] |
| No | 344 [96.9] | 54 [85.7] | 290 [99.3] |
| Case pathologies | |||
| Cancer [Category 1], n [%] | 30 [8.5] | ||
| Left-sided | Right-sided | ||
| Stage I | 2 | 0 | |
| Stage II | 4 | 4 | |
| Stage III | 6 | 6 | |
| Stage IV | 1 | 1 | |
| Stage unknown | 3 | 3 | |
| APL [Category 2], n [%] | 33 [9.3] | ||
| Category 2.1—Adenoma, HGD | 1 | ||
| Category 2.2—Adenoma, villous growth | 0 | ||
| Category 2.3—Adenoma ≥ 1 cm | 1 | ||
| Category 2.4—Sessile serrated polyp, serrated lesion ≥ 1 cm | 7 | ||
| Category 2.5—IBD-HGD, any size | 11 | ||
| Category 2.6—IBD-LGD, ≥ 1 cm | 13 | ||
| Non-advanced precancerous lesions [Categories 3–5], n [%] | 27 [7.6] | ||
| Category 3—1 or 2 adenomas > 0.5 cm, <1 cm, IBD-LGD < 1 cm | 13 | ||
| Category 4—≥3 adenomas, < 1 cm | 1 | ||
| Category 5—1 or 2 adenomas, ≤ 0.5 cm | 13 | ||
| Negative [Category 6]a, n [%] | 265 [74.7] | ||
IQR: interquartile range; APL: advanced precancerous lesions; HGD: high-grade dysplasia; LGD: low-grade dysplasia; IBD-HGD/LGD: inflammatory bowel disease-associated dysplasia [high- or low-grade].
aIncludes hyperplastic polyps <1 cm and no findings.